Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...
Lilly's success doesn't depend entirely on its obesity drug, though. Mounjaro, which is approved for type 2 diabetes, is the same drug under the hood as Zepbound and also has tremendous commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results